Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease

The Journal of Pharmacology and Experimental Therapeutics
Rina AharoniRuth Arnon

Abstract

Inflammatory bowel disease (IBD) is characterized by detrimental immune reactivity in the gut and imbalance between proinflammatory and anti-inflammatory reactivity. In an attempt to down-regulate colitis, we investigated the effect of the immunomodulator glatiramer acetate (GA, Copaxone, copolymer 1) on two murine models of IBD, chemically induced and spontaneous. Acute experimental colitis of different levels of severity was induced in C57BL/6 mice by dextran sulfate sodium (DSS) administered orally at different concentrations and frequencies. It was manifested in weight loss, intestinal bleeding, and diarrhea, as well as by macroscopic and microscopic colon damage. GA treatment led to amelioration of all of these pathological manifestations, resulting in improved long-term survival. Moreover, even when colitis was induced by three cycles of DSS in this highly susceptible mouse strain, as well as in BALB/c mice that exhibit a chronic disease pattern, a substantial reduction in disease activity and mortality was obtained. GA treatment induced a beneficial effect also in a spontaneous model of colitis developed in the C3H/HeJBir IL-10-deficient mice. The detrimental proinflammatory response manifested by proliferation, tumor ne...Continue Reading

References

Jun 1, 1996·The Journal of Experimental Medicine·M F NeurathW Strober
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·R AharoniR Arnon
Apr 2, 1998·World Journal of Surgery·G Rogler, T Andus
Dec 9, 1998·Clinical and Experimental Immunology·L A DielemanE P Van Rees
Mar 31, 1999·Proceedings of the National Academy of Sciences of the United States of America·D TeitelbaumM Sela
Mar 25, 2000·Journal of Leukocyte Biology·R Boismenu, Y Chen
Jun 22, 2000·Proceedings of the National Academy of Sciences of the United States of America·O NeuhausR Hohlfeld
May 8, 2002·The Journal of Experimental Medicine·M F NeurathR S Blumberg
May 23, 2002·Gastroenterology·William J Sandborn, Stephan R Targan
Dec 14, 2002·Inflammatory Bowel Diseases·Michael Mähler, Edward H Leiter
Nov 14, 2003·Proceedings of the National Academy of Sciences of the United States of America·Rina AharoniRuth Arnon
Jan 17, 2004·The European Journal of Neuroscience·Sarit Edelheit, Noam Meiri
Jan 21, 2004·Journal of Molecular Recognition : JMR·Ruth Arnon, Michael Sela
Jun 28, 2005·Critical Reviews in Oncology/hematology·John H Kwon, Richard J Farrell
Aug 20, 2005·Lancet Neurology·Cinthia FarinaReinhard Hohlfeld
Nov 4, 2005·The New England Journal of Medicine·William J SandbornUNKNOWN Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group
Nov 18, 2005·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Chamutal GurRifaat Safadi

❮ Previous
Next ❯

Citations

Jul 16, 2008·Inflammatory Bowel Diseases·Albrecht NeesseMartin Steinkamp
Mar 12, 2010·Inflammatory Bowel Diseases·N MaharshakI Shachar
Apr 29, 2010·BMC Chemical Biology·Moul DeyIlya Raskin
Jan 21, 2010·Journal of Visualized Experiments : JoVE·Caitlyn G WhittemChristopher S Williams
Apr 16, 2013·The Journal of Surgical Research·Gulay Erdogan KayhanMehmet Özcan Ersoy
Mar 16, 2011·Journal of Neuroimmunology·Mrinalini KalaTimothy Vollmer
Jun 17, 2010·European Journal of Pharmacology·Uruguaysito BenavidesLeonard D Kohn
Dec 16, 2011·Immunological Reviews·Neeraj K Surana, Dennis L Kasper
Feb 24, 2015·Digestive Diseases and Sciences·Doron YablecovitchFred M Konikoff
May 2, 2015·BMC Anesthesiology·Jianxing ZhangHongying Li
Nov 4, 2015·Inflammatory Bowel Diseases·Einat Zelman-ToisterIdit Shachar
Mar 28, 2012·Expert Review of Neurotherapeutics·Kenneth P Johnson
Jul 3, 2019·Assay and Drug Development Technologies·Hermann A M Mucke
Feb 12, 2011·The Journal of Pharmacology and Experimental Therapeutics·Doron YablecovitchRuth Arnon
Mar 17, 2015·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Brandi L CantarelEllen M Mowry
Mar 25, 2011·Immunopharmacology and Immunotoxicology·Erol AktuncFigen Barut
Aug 2, 2016·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Kazumasa Yokoyama, Nobutaka Hattori
Apr 30, 2017·Advanced Drug Delivery Reviews·Sean H KellyJoel H Collier
Apr 27, 2021·Biomaterials·Nicole L VotawJoel H Collier
May 28, 2021·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Kufreobong E InyangGeoffroy Laumet
Aug 31, 2021·Therapeutic Advances in Neurological Disorders·Tobias BrummerStefan Bittner

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.